Brewer's Yeast

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: energy digestion immunity

Research Overview

Research on brewer’s yeast (typically Saccharomyces cerevisiae and related brewing strains) spans two main domains: (1) food and fermentation science and (2) human health/nutrition applications. In brewing and food technology, studies frequently characterize how different yeast strains and processing conditions influence beer aroma and flavor through volatile compounds (e.g., higher alcohols, esters, aldehydes, terpenoids), and how yeast autolysis and cell-wall composition (β-glucans, mannoproteins, chitin) affect product quality and potential recovery of functional ingredients. A related applied-food area examines yeast-derived components (notably β-glucans) as functional additives (e.g., as texturizers/thickeners in yogurt), assessing effects on fermentation kinetics, texture, and sensory acceptance.

In clinical and translational health research, brewer’s yeast appears most often as (a) a dietary exclusion target in hidradenitis suppurativa (HS) and (b) a chromium-containing supplement evaluated for glycemic outcomes in type 2 diabetes. The strongest evidence in the provided abstracts is for a modest reduction in fasting plasma glucose with brewer’s yeast supplementation in type 2 diabetes (meta-analysis signal for fasting glucose but not for A1C), suggesting at best a marginal metabolic benefit over short follow-up periods. For HS, multiple reviews identify dietary avoidance of brewer’s yeast among non-pharmacologic strategies with reported benefit, but the evidence base is described as limited—dominated by small, heterogeneous, and often non-randomized or single-arm studies—so conclusions about efficacy and generalizability remain tentative. Other mentions (e.g., brewer’s yeast as a pyrexia inducer in animal models) reflect its use as a research tool rather than evidence of direct therapeutic benefit.

Key gaps include the need for well-powered randomized controlled trials to test brewer’s yeast exclusion diets in HS with standardized outcomes, clear definitions of “brewer’s yeast” exposure (food sources vs supplements), and control for confounders such as weight loss and concurrent therapies. For metabolic outcomes, more rigorous trials are needed to determine which yeast preparations (whole yeast vs chromium-enriched yeast vs isolated fractions), doses, and durations meaningfully affect clinically relevant endpoints beyond fasting glucose (e.g., A1C, insulin sensitivity, cardiovascular risk markers), and to clarify safety/tolerability. In parallel, mechanistic work linking specific yeast components (e.g., β-glucans, mannoproteins, fermentation-derived metabolites) to immunometabolic or inflammatory pathways would help bridge the current divide between strong fermentation/food-chemistry characterization and comparatively weaker clinical evidence.

1. What conditions has Brewer's Yeast been studied for?

  • Hidradenitis suppurativa (HS): Studied mainly via dietary avoidance/exclusion of brewer’s yeast as a non-pharmacologic intervention (review-level evidence; systematic review/review articles referenced in the abstracts).

  • Type 2 diabetes mellitus (T2DM): Studied as brewer’s yeast supplementation (often in the context of chromium-containing yeast) for effects on glycemic markers (A1C and fasting plasma glucose).

  • Fever/inflammation models (preclinical): Brewer’s yeast (Saccharomyces cerevisiae) used to induce pyrexia in animal experiments; interventions were tested against “brewer’s yeast–induced pyrexia” (this is a research model, not brewer’s yeast as a treatment).

  • Gut permeability/inflammation markers (animal nutrition): A concentrated brewer’s yeast product (providing β-glucan) studied in dogs for intestinal permeability markers and inflammatory/oxidative markers.

  • Food/functional ingredient applications: Brewer’s yeast–derived β-glucan incorporated into yogurt to assess physicochemical and sensory effects (food technology rather than a clinical condition).

  • Selenium metabolism (comparative yeast biology): Work comparing selenium compound formation in Torula yeast vs brewer’s yeast (biochemical/nutritional chemistry; not a clinical endpoint in the abstract provided).

2. Does it work in treating those conditions? Summarize the evidence.

  • HS (via brewer’s yeast avoidance, not supplementation): Reviews cited in the abstracts state that “brewer’s yeast exclusion diets have the potential to ameliorate the signs of HS” and list “dietary avoidance of brewer’s yeast” among non-pharmacologic modalities with evidence of efficacy. However, the same review emphasizes major limitations: predominance of pilot/single-arm studies, heterogeneity, and lack of randomized controlled trials. Overall: suggestive but low-certainty evidence that avoiding brewer’s yeast may help some HS patients.

  • T2DM (brewer’s yeast supplementation): A meta-analysis of 14 RCTs (n=875; 8–24 weeks) reported that brewer’s yeast supplementation produced a statistically significant reduction in fasting plasma glucose of -19.23 mg/dL (95% CI -35.30 to -3.16; I(2)=21%; n=137) versus placebo/control, but no significant effect on A1C. Overall: modest improvement in fasting glucose without clear evidence of improved longer-term glycemic control (A1C).

  • Gut permeability/inflammation (dogs): In a 10-week randomized feeding study (n=20 dogs), yeast supplementation (β-glucan dose 7 mg/kg/day) tended to reduce permeability marker exposure (iohexol I-AUC P=0.10; Cr-EDTA I-AUC P=0.06) and significantly lowered haptoglobin (P ≤ 0.05), with no differences in serum amyloid A or malondialdehyde. This is animal evidence and cannot be assumed to translate to humans.

  • Fever/inflammation model: Brewer’s yeast is used to induce fever in animals; the abstract provided tested essential oils that reduced brewer’s yeast–induced pyrexia. This does not show brewer’s yeast treats fever; it is the provoking agent in the model.

3. What health benefits does it have?

  • Potential glycemic benefit in T2DM: Brewer’s yeast supplementation was associated with a modest reduction in fasting plasma glucose (-19.23 mg/dL) in a meta-analysis, though without A1C improvement (suggesting limited or uncertain clinical impact over time).

  • Potential gut barrier/support effects (animal evidence): Concentrated brewer’s yeast (β-glucan-containing) in dogs was associated with trends toward reduced intestinal permeability and lower haptoglobin, suggesting possible gut-barrier or inflammatory-modulating effects in that model.

  • Bioactive polysaccharides (mechanistic/functional food rationale): A review notes yeast cell wall polysaccharides (e.g., β-glucans, mannoproteins) have “outstanding health effects” and are recommended for functional foods, supporting plausibility for immune/metabolic effects, though the abstract does not provide human clinical outcomes.

  • Food formulation utility (not a direct health outcome): Brewer’s yeast β-glucan (Yestimun) altered yogurt texture and reduced fermentation time; this supports use as a functional ingredient, but does not itself demonstrate a health benefit in consumers.

4. Does it have any downsides or side effects?

  • Possible HS worsening in susceptible individuals (dietary trigger): Multiple HS-focused reviews highlight dietary avoidance of brewer’s yeast as potentially beneficial, implying brewer’s yeast ingestion may exacerbate HS symptoms in some patients. The abstracts do not quantify frequency or magnitude, and evidence quality is limited (small, heterogeneous, often non-randomized studies).

  • Palatability/aftertaste issues in foods: Yogurt fortified with brewer’s yeast β-glucan at 0.8% (wt/wt) reduced overall acceptance due to adverse flavor/aftertaste (sensory panel n=40). This is a tolerability/acceptability downside rather than a medical adverse effect.

  • General safety limitations in the provided abstracts: The included abstracts do not report a detailed adverse-event profile for brewer’s yeast supplementation in humans (e.g., GI effects, allergy, interactions). Therefore, side-effect conclusions from these abstracts are limited.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (no genotype-stratified responses, no gene–nutrient interactions, and no variant-specific safety signals) for brewer’s yeast, brewer’s yeast exclusion diets, chromium yeast, or yeast-derived β-glucans. Therefore, based on these abstracts alone, there is no evidence that brewer’s yeast is specifically beneficial or harmful for particular genetic variations.

References

  1. Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review.
    Arunima Sivanand, Wayne P Gulliver, Chitmandeep K Josan, Raed Alhusayen, Patrick J Fleming (2020) - Journal of cutaneous medicine and surgery
  2. Evaluation of volatile compound profiles and sensory properties of dark and pale beers fermented by different strains of brewing yeast.
    Justyna Paszkot, Alan Gasiński, Joanna Kawa-Rygielska (2023) - Scientific reports
  3. The role of nutrition in acne vulgaris and hidradenitis suppurativa.
    Aziz Khan, Mary Wu Chang (2022) - Clinics in dermatology
  4. Impact of plasmolysis process on the enrichment of brewer's spent yeast biomass with vitamin D
    Tatielly de Jesus Costa, Marcelo Thomazini, Julia Cristina José, Ramon Peres Brexó, Milena Martelli-Tosi, Carmen Sílvia Favaro-Trindade (2024) - Food research international (Ottawa, Ont.)
  5. Effect of chromium supplementation on glycated hemoglobin and fasting plasma glucose in patients with diabetes mellitus.
    Raynold V Yin, Olivia J Phung (2015) - Nutrition journal
  6. Cell wall polysaccharides: before and after autolysis of brewer's yeast.
    Jinjing Wang, Mengqi Li, Feiyun Zheng, Chengtuo Niu, Chunfeng Liu, Qi Li, Jinyuan Sun (2018) - World journal of microbiology & biotechnology
  7. Non-pharmacologic approaches for hidradenitis suppurativa - a systematic review
    Aleksi J Hendricks, Penelope A Hirt, Sahil Sekhon, Alexandra R Vaughn, Hadar A Lev-Tov (2021)
  8. Comparative study on eucalyptol and camphor rich essential oils from rhizomes of Hedychium spicatum Sm. and their pharmacological, antioxidant and antifungal activities.
    Avneesh Rawat, Manju Rawat, O M Prakash, Ravendra Kumar, Himanshu Punetha, Dharmendra S Rawat (2022) - Anais da Academia Brasileira de Ciencias
  9. Use of β-glucan from spent brewer's yeast as a thickener in skimmed yogurt: Physicochemical, textural, and structural properties related to sensory perception.
    Vassilios Raikos, Shannon B Grant, Helen Hayes, Viren Ranawana (2018) - Journal of dairy science
  10. A proof of principle study investigating the effects of supplemental concentrated brewer's yeast on markers of gut permeability, inflammation, and fecal metabolites in healthy non-challenged adult sled dogs.
    Lindsey M Rummell, Michael A Steele, James R Templeman, Taylor T Yohe, Nadeem Akhtar, Jocelyn G Lambie, Pawanpreet Singh, Thomas Asquith, Adronie Verbrugghe, Wendy Pearson, Anna K Shoveller (2022) - Journal of animal science
  11. Acute Effects of Turmeric Extracts on Knee Joint Pain: A Pilot, Randomized Controlled Trial.
    Lorena Calderón-Pérez, Elisabet Llauradó, Judit Companys, Laura Pla-Pagà, Noemí Boqué, Francesc Puiggrós, Rosa-M Valls, Anna Pedret, Josep Manuel Llabrés, Lluís Arola, Rosa Solà (2021) - Journal of medicinal food
  12. Identification and determination of selenohomolanthionine - The major selenium compound in Torula yeast.
    Katarzyna Bierła, Noriyuki Suzuki, Yasumitsu Ogra, Joanna Szpunar, Ryszard Łobiński (2017) - Food chemistry
  13. Expert consensus on priority research gaps in dietary and lifestyle factors in hidradenitis suppurativa: a Delphi consensus study.
    Mika Yamanaka-Takaichi, Rishab Revankar, Terri Shih, Margaret Gall, Jennifer L Hsiao, Vivian Y Shi, Afsaneh Alavi (2023) - Archives of dermatological research
  14. Effects of replacing fishmeal with different proportions of mixed protein source in the diet of largemouth bass (Micropterus salmoides).
    Liutong Chen, Jian Zhong, Menglin Shi, Yucheng Liu, Kangyuan Qu, Beiping Tan, Huijun Yang, Shiwei Xie (2024) - Comparative biochemistry and physiology. Part D, Genomics & proteomics
  15. Analgesic, Anti-inflammatory, Antipyretic, andIn SilicoMeasurements ofSonneratia caseolaris(L.) Fruits from Sundarbans, Bangladesh
    Pritam Kundu, Shovan Lal Debnath, Hiron Saraj Devnath, Lopa Saha, Samir Kumar Sadhu (2022)
  16. Effect of supplementation with brewer's yeast hydrolysate on growth performance, nutrients digestibility, blood profiles and meat quality in growing to finishing pigs.
    Jian Ying Zhang, Jae Won Park, In Ho Kim (2019) - Asian-Australasian journal of animal sciences
  17. Use of a commercial feed supplement based on yeast products and microalgae with or without nucleotide addition in calves.
    Aristide Maggiolino, Gerardo Centoducati, Elisabetta Casalino, Gabriella Elia, Tiziana Latronico, Maria Grazia Liuzzi, Luigi Macchia, Geoffrey E Dahl, Gianluca Ventriglia, Nicola Zizzo, Pasquale De Palo (2023) - Journal of dairy science
  18. Effect of spent brewer's yeast β-D-glucan on properties of wheat flour dough and bread during chilled storage.
    Sarinthorn Suwannarong, Rungtiwa Wongsagonsup, Manop Suphantharika (2020) - International journal of biological macromolecules
  19. Optimization of Brewer's Yeast Quantity in Liquid and Gel Larval Diets for the Mediterranean Fruit Fly.
    Paraschos N Prekas, Vasilis G Rodovitis, Evmorfia P Bataka, David Nestel, Christos T Nakas, Nikos T Papadopoulos (2023) - Insects
  20. The Analgesic, Anti-Inflammatory and Anti-Pyretic Activities of Tinospora cordifolia.
    Liaqat Hussain, Muhammad S H Akash, Noor-Ul Ain, Kanwal Rehman, Muhammad Ibrahim (2015) - Advances in clinical and experimental medicine : official organ Wroclaw Medical University


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!